Novel mdm2 splice variants identified in pediatric rhabdomyosarcoma tumors and cell lines

Oncology Research

Volumn 12, Issue 11-12, 2000, Pages 451-457

  Bartel, Frank ^a,b   Taylor, Alan C ^a   Taubert, Helge ^b   Harris, Linda C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Isoforms; mdm2; p53; Pediatric; Rhabdomyosarcoma

Indexed keywords

MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; RNA; TUMOR PROTEIN;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER STAGING; CELL CULTURE; CHILD; GENETIC VARIABILITY; GENETICS; HUMAN; NORTHERN BLOTTING; ONCOGENE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA;

ALTERNATIVE SPLICING; BLOTTING, NORTHERN; CHILD; HUMANS; NEOPLASM PROTEINS; NEOPLASM STAGING; NUCLEAR PROTEINS; ONCOGENES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RNA, NEOPLASM; TUMOR CELLS, CULTURED; VARIATION (GENETICS);

EID: 0034584527     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504001108747459     Document Type: Article

References (22)

1. Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. J. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245; 1992.
2. Momand, J.; Jung, D.; Wilczynski, S.; Niland, J. The MDM2 gene amplification data base. Nucleic Acids Res. 26:3453-3459; 1998.
3. Bartel, F.; Meye, A.; Wurl, P.; Kappler, M.; Bache, M.; Lautenschlager, C.; Grunbaum, U.; Schmidt, H.; Taubert, H. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 mRNA, is associated with prognosis in soft tissue sarcoma. Int. J. Cancer 95:168-175; 2001.
4. Taylor, A. C.; Shu, L.; Danks, M. K.; Poquette, C. A.; Shetty, S.; Thayer, M. J.; Houghton, P. J.; Harris, L. C. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med. Pediatr. Oncol. 35:96-103; 2000.
5. Cordon-Cardo, C.; Latres, E.; Drobnjak, M.; Oliva, M.-R.; Pollack, D.; Woodruff, J. M.; Marechal, V.; Chen, J.; Brennan, M. F.; Levine, A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54:794-799; 1994.
6. Dubs-Poterszman, M. C.; Tocque, B.; Wasylyk, B. MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. Oncogene 11:2445-2449; 1995.
7. Jones, S. N.; Hancock, A. R.; Vogel, H.; Donehower, L. A.; Bradley, A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA 95:15608-15612; 1998.
8. Sigalas, I.; Calvert, A. H.; Anderson, J. J.; Neal, D. E.; Lunec, J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer. Nat. Med. 2:912-917; 1996.
9. Lukas, J.; Gao, D.-Q.; Keshmeshian, M.; Wen, W.-H.; Tsao-Wei, D.; Rosenberg, S.; Press, M. F. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res. 61:3212-3219; 2001.
10. Matsumoto, R.; Tada, M.; Nozaki, M.; Zhang, C. L.; Sawamura, Y.; Abe, H. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res. 58:609-613; 1998.
11. Kraus, A.; Neff, F.; Behn, M.; Schuermann, M.; Muenkel, K.; Schlegel, J. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells. Int. J. Cancer 80:930-934; 1999.
12. Tamborini, E.; Della Torre, G.; Lavarino, C.; Azzarelli, A.; Carpinelli, P. Analysis of the molecular species generated by mdm2 gene amplification in liposarcomas. Int. J. Cancer 92:790-796; 2001.
13. Schlott, T.; Reimer, S.; Jahns, A.; Ohlenbusch, A.; Ruschenburg, I.; Nagel, H.; Droese, M. Point mutations and nucleotide insertions in the MDM2 zinc finger structure of human tumours. J. Pathol. 182:54-61; 1997.
14. Sambrook, J.; Fritsch, E. F.; Maniatis, T. Molecular cloning: A laboratory manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Press; 1989.
15. McPake, C. R.; Tillman, D. M.; Poquette, C. A.; George, E. O.; Houghton, J. A.; Harris, L. C. Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status. Oncol. Res. 10:235-244; 1998.
16. Anderson, L.; Seilhamer, J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18:533-537; 1997.
17. Evans, S. C.; Viswanathan, M.; Grier, J. D.; Narayana, M.; ElNaggar, A. K.; Lozano, G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene 20: 4041-4049; 2001.
18. Sharp, D. A.; Kratowicz, S. A.; Sank, M. J.; George, D. L. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem. 274:38189-38196; 1999.
19. Tanimura, S.; Ohtsuka, S.; Mitsui, K.; Shirouzu, K.; Yoshimura, A.; Ohtsubo, M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 447:5-9; 1999.
20. Jiang, Z. H.; Wu, J. Y. Alternative splicing and programmed cell death. Proc. Soc. Exp. Biol. Med. 220:64-72; 1999.
21. Taubert, H.; Koehler, T.; Meye, A.; Bartel, F.; Lautenschlager, C.; Borchert, S.; Bache, M.; Schmidt, H.; Wurl, P. mdm2 mRNA level is a prognostic factor in soft tissue sarcoma. Mol. Med. 6: 50-59; 2000.
22. Wurl, P.; Meye, A.; Berger, D.; Lautenschlager, C.; Bache, M.; Holzhausen, H. J.; Schmidt, H.; Dralle, H.; Rath, F. W.; Taubert, H. Significance of retinoblastoma and mdm2 gene expression as prognostic markers for soft-tissue sarcoma. Langenbecks Arch. Surg. 383:99-103; 1998.